F S&P 500
5,481.00 +4.25 (+0.08%) F Dow Jones
39,161.00 +14.00 (+0.04%) F Nasdaq
19,802.00 +38.75 (+0.20%) E-mini Russell 2000 Index Futur
2,043.80 +4.10 (+0.20%) Petróleo
82.34 +0.17 (+0.21%) Oro
2,377.40 +8.40 (+0.35%)
SQZ Biotechnologies Company (SQZB)
SQZ Biotechnologies Company
200 Arsenal Yards Boulevard
Suite 210
Watertown, MA 02472
United States
617 758 8672
https://www.sqzbiotech.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 53
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Howard Bernstein M.D., Ph.D. | Interim CEO & Director | 552.14k | N/D | 1957 |
| Mr. Lawrence J. Knopf Esq. | General Counsel & Secretary | 512.38k | N/D | 1962 |
| Dr. Marshelle Smith Warren M.D. | Chief Medical Officer | 476.27k | N/D | 1964 |
| Dr. Robert S. Langer Jr., Ph.D., ScD | Co-Founder & Member of Scientific Advisory Board | N/D | N/D | 1949 |
| Mr. Richard V. Capasso CPA | Chief Accounting Officer | N/D | N/D | 1962 |
| Mr. David First | Chief People Officer | N/D | N/D | 1964 |
| Ipsita Roymoulik Ph.D. | Senior Vice President of CMC & QUALITY | N/D | N/D | N/D |
Descripción
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de SQZ Biotechnologies Company a partir del 1 de junio de 2024 es 8. Las puntuaciones principales son Auditoría: 4; Junta: 7; Derechos del accionista: 9; Compensación: 9.
